The “PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate” trial proposes using MP for risk assessment to guide neoadjuvant treatment in patients who are not candidates for BCS. Here, ERBB2 is linked to breast carcinoma.